AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03048370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left cold CVS
Description: Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
Study NCT03048370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right cold CVS
Description: Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
Study NCT04680078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum
Description: A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
Study NCT04680078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Triangular Three-snip Punctoplasty of the lower punctum
Description: A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
Study NCT02472925 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MedSignals Pill Box
Description: Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
Study NCT02472925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedSignals Pill Box
Description: Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
Study NCT03057457 — intervention group
Intervention type: DEVICE
Intervention: NGAL Test
Description: The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
Study NCT03195855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy / joint mobilisations
Description: Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
Study NCT03065634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to work and living healthy after head and neck cancer
Description: Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
Study NCT03065634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: socio-legal counseling
Description: Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker
Study NCT04146831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
Study NCT02336516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
Study NCT02336516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (glucose solution 10%)
Study NCT02389101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTANOC PET/CT; Diffusion weighted MRI
Description: PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
Study NCT02087384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Intramuscular Gardasil vaccination at 0, 2 and 6 months.
Study NCT02087384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection of 0.9% saline
Study NCT00920894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant stanol ester
Description: the effect of plant stanol esters on plasma lipids
Study NCT01752582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BuMA stent
Description: About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
Study NCT01752582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EXCEL stent
Description: About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
Study NCT01987167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Description: Injectable Gel
Study NCT04705558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous moderate intensity aerobic training
Description: continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
Study NCT04705558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
Study NCT04507867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional support system (NSS)
Description: 1. Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~2. Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~3. One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system.
Study NCT04507867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional nutritional support designed by hospital nutritionists
Description: Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
Study NCT04507867 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional nutritional support designed by hospital nutritionists
Description: Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
Study NCT03128216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind Local Anesthetic infiltration
Description: Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
Study NCT03128216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversals Fascia Block
Description: Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
Study NCT03128216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Patients of this group received Spinal Anesthesia
Study NCT03128216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic used for local infiltration and Transversals fascia block
Study NCT03128216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local anesthetic used for Spinal Anesthesia
Study NCT00920894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant stanol ester
Description: the effect of plant stanol esters on plasma lipids
Study NCT01680874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
Study NCT01680874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
Study NCT01094028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
Study NCT04012372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROSA Water
Description: Ad libitum hydration with ROSA oligomineral water
Study NCT04012372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control water
Description: Ad libitum hydration with other waters
Study NCT02572349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Study NCT02572349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT00932282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Oral Immunotherapy
Description: Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
Study NCT00932282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
Study NCT01706016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermic destruction of tissue by Laser using the Novilase device
Study NCT01473576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate
Description: 0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
Study NCT01473576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 0.15 mmol sodium chloride dissolved in 250 mL water.
Study NCT01914523 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh
Description: Laryngeal exposure and tracheal intubation using that device
Study NCT01914523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision
Description: Laryngeal exposure and tracheal intubation using that device
Study NCT01914523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Laryngeal exposure and tracheal intubation using that device
Study NCT01914523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirTraq
Description: Laryngeal exposure and tracheal intubation using that device
Study NCT04851275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physicians trained in shared decision making
Description: Physicians in this group were trained in shared decision making
Study NCT04851275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physicians were not trained in shared decision making
Description: Physicians did not receive training in shared decision making
Study NCT01645202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Comparison of different types of valves
Study NCT04400825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
Study NCT04400825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
Study NCT03209635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
Study NCT03209635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
Study NCT03235869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
Study NCT03235869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
Study NCT01320020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab
Description: Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
Study NCT04119219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata.
Study NCT02555566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
Study NCT02555566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flow-mediated distal stimulation of the forearm radial artery by cutaneous heating
Description: Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
Study NCT02857335 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neurocognitive tests
Description: Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
Study NCT02607358 — intervention group
Intervention type: OTHER
Intervention: blood sampling for HOTPR-testing
Description: All subjects are tested for responderstatus using the VerifyNow System
Study NCT01869166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-EGFR
Study NCT04058054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat® Cream
Description: Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
Study NCT04834921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultraflux® EMiC®2
Description: Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
Study NCT04834921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraflux® EMiC®2
Description: Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
Study NCT02101905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02101905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02101905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Given PO
Study NCT02101905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Given PO
Study NCT02101905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT02101905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT02101905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02101905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02101905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor
Study NCT02101905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor
Study NCT02266160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream 5%
Description: the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days.
Study NCT02266160 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: cetomacrogol cream (lotion cream)
Description: lotion cream that does not contain active drug. has no contraindications
Study NCT02695381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac-lidocaine topical patch
Description: Once daily
Study NCT03274622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact Parent Training
Study NCT03274622 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Impact
Study NCT02649595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Red Cross Respite care
Description: See detailed description.
Study NCT02244112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
Study NCT02244112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
Study NCT02695381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT02550067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
Study NCT03375606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL730
Description: Solution for IV infusion